4Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: Incidence and precipitating factors. Am J Dig Dis, 1976,21:953-956.
5Pan GZ, Xu GM, Ke MY, et al. Epidemiological study of symptomatic gastroesophageal reflux disease in China: Beijing and Shanghai. Chin J Dig Dis ,2000, 1:2-8.
6Williams MP, Sercombe J, Hamilton MI, et al. A placebocontrolled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.Aliment Pharmacol Ther, 1998,12:1079-1089.
7Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole.Aliment Pharmacol Ther , 1999,13(suppl 3): 27-36.
8Besancon M, Simon A, Sachs G, et al. Sites of reaction of the gastric H-K-ATPase with extracytoplasmic thiol reagents. J Biol Chem ,1997,272 :22438-22446.
9Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: A progress report on observer agreement. Gastroenterology, 1996,111: 85-92.
10de Carle DJ. Gastrooesophageal reflux disease. Med J Aust,1998,169:549-554.
9Curran MP, Robinson DM. Robinson. Mosapride in gastrointestinal dísorders.Drugs,2008,68:981-991.
10Madan K,Ahuja V,Kashyap PC,et al. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal re? ux disease: a randomized trial.Dis Esophagus,2004,17:274-278.
